"Omega-3 fatty acids have been known for their cardioprotective effects and they have broad anti-inflammatory properties, ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

Significant reductions in proteinuria, estimated glomerular filtration rate stability of the C3/C3b inhibitor were also ...

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial presented during a ...

Phase II CONFIDENCE study data reveal that simultaneous initiation of Kerendia and Jardiance significantly improves UACR and ...

New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Patients who develop LN within 1 to 5 years after SLE onset may face poorer renal outcomes compared with those who develop the disease earlier.

The VALIANT Phase 3 trial shows that pegcetacoplan significantly reduces proteinuria and stabilises kidney function in ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

The S&P 500 index is one of the most widely followed stock market indexes in the world, with trillions of dollars managed based on its makeup. When companies are added or removed from the index ...